Guangzhou Lanbo

Guangzhou Lanbo Biotechnology Co., Ltd. focuses on the POCT-LFI (Fluorescence Immunoassay Lateral Flow Technology) field, committed to advancing chromatography technology and innovating testing techniques, safeguarding national health through medical technology. Lanbo Bio possesses a complete domestic POCT-LFI product line, one of the world's largest-scale POCT-LFI production lines, and the most LFI invention patents. We aim to provide high-quality solutions for a wide range of corporate and industry users through continuous technological innovation.
Currently, Lanbo Bio has over 250 employees (more than 80 researchers), with production and R&D bases in Guangdong, serving fields such as medical testing (laboratory and pathology), food safety, inspection and quarantine, pet healthcare, emergency rescue, drug testing, forensic science, and military medicine, with a domestic market share exceeding 70%. International business spans 36 countries and regions.
Since the company's establishment in 2007, Lanbo Bio has been committed to continuous technological advancement, possessing strong competitiveness and independent intellectual property rights in fields such as mechanical automation, integrated circuits, biotechnology, optical technology, and image processing technology, with comprehensive solutions and services. In 2019, domestically advanced fully automated POCT-LFI testing systems, world-original multi-wavelength LFI fluorescence immunoassay automation systems, and innovative fully automated pathological staining systems are set to be launched sequentially...